Nykode Therapeutics ASFRA:5VB -0.61%37 PB Ratio is 1.06 as of Jun. 29, 2026, which is 75% below its 10-year median of 4.20. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Nykode Therapeutics AS ranks better than 76.22% on this metric.
Nykode Therapeutics AS stock PB Ratio (=1.25) is close to 1-year high of 1.25.
The historical rank and industry rank for Nykode Therapeutics AS's PB Ratio or its related term are showing as below:
FRA:5VB'
s PB Ratio Range Over the Past 10 Years
Min: 0.39 Med: 4.2 Max: 17.3
Current: 1.25
During the past 9 years, Nykode Therapeutics AS's highest PB Ratio was 17.30. The lowest was 0.39. And the median was 4.20.
FRA:5VB's PB Ratio is ranked better than 76.22% of 1232
companies
in the Biotechnology industry
Industry Median: 2.815
vs FRA:5VB: 1.25
During the past 12 months, Nykode Therapeutics AS's average Book Value Per Share Growth Rate was -40.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -18.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -10.80% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Nykode Therapeutics AS was 135.60% per year. The lowest was -18.70% per year. And the median was 41.00% per year.
Back to Basics: PB Ratio
Nykode Therapeutics AS (FRA:5VB) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nykode Therapeutics AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nykode Therapeutics AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nykode Therapeutics AS's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nykode Therapeutics AS (FRA:5VB) has a PB Ratio of 1.06 as of Jun. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nykode Therapeutics AS and its competitors. This is 75% below median its historical median of 4.20. Over the past decade, Nykode Therapeutics AS's PB Ratio has ranged from 0.39 to 17.30. According to the industry distribution chart, Nykode Therapeutics AS ranks #293 out of 1232 companies in the Biotechnology industry, placing it in the top 23.8%.
Is Nykode Therapeutics AS's PB Ratio too high?
Nykode Therapeutics AS's current PB Ratio of 1.06 is 75% below median its 10-year median of 4.20. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 17.30. The Biotechnology industry median PB Ratio is 2.82. Nykode Therapeutics AS's value of 1.06 is 62.3% below this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #293 out of 1232 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #293 out of 1232 companies for PB Ratio. This places Nykode Therapeutics AS in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.82. Nykode Therapeutics AS's value of 1.06 is 62.3% below this benchmark. Historically, Nykode Therapeutics AS's own PB Ratio has ranged from 0.39 to 17.30 over the past decade. While the company's 10-year median is 4.20 vs. the industry median of 2.82, Nykode Therapeutics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current PB Ratio of 1.06 is 62.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nykode Therapeutics AS and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current PB Ratio is 1.06, which is 75% below median its own 10-year median of 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current PB Ratio is 1.06, which is 75% below median its 10-year median of 4.20 and 62.3% below the Biotechnology industry median of 2.82. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current PB Ratio is 1.06 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?
Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued.
The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49.
GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.
Key valuation signals for FRA:5VB:
PB Ratio: 1.06 (75% below median its 10-year median of 4.20)
GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
Industry Position: 62.3% below the Biotechnology median (#293 of 1232)
No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score
Get the complete analysis for FRA:5VB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5VB has been successfully added to your 
